Report Detail
Global Peptide-Drug Conjugates Market Report, History and Forecast 2017-2028, Breakdown Data by Companies, Key Regions, Types and Application
- RnM4422810 |
- 13 April, 2022 |
- Global |
- 88 Pages |
- QYResearch |
- Medical Industry
Summary:
Market Insights
The research report studies the Peptide-Drug Conjugates market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
Due to the COVID-19 pandemic, the global Peptide-Drug Conjugates market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028.
The global main companies of Peptide-Drug Conjugates include AstraZeneca, Bicycle Therapeutics, Cybrexa Therapeutics, Esperance Pharmaceuticals, Oncopeptides, Pepgen Corporation, Soricimed Biopharma and Theratechnologies, etc. In 2021, the global six largest players have a share approximately % in terms of revenue.
The North America Peptide-Drug Conjugates market is estimated at US$ million in 2021, while China is forecast to reach US$ million by 2028. The proportion of the China is % in 2021 and it is predicted that the share will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. As for the Europe Peptide-Drug Conjugates landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Cell-penetrating Peptides (CPPs) accounting for % of the Peptide-Drug Conjugates global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Carcinoma segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
Segment Scope
An intensive study of key type and application segments has been done in this segmentation section. The authors of the report have provided reliable figures including revenue forecast data by type and application for the period 2017-2028. They have also studied how the segments are gaining or losing growth in various geographies and their respective countries. Thanks to this study, readers can thoroughly grasp the growth pattern and potential of different segments.
Segment by Type
Cell-penetrating Peptides (CPPs)
Cell-targeting Peptides (CTPs)
Segment by Application
Carcinoma
Sarcoma
Melanoma
Lymphoma
Leukemia
Regional Scope
This segment of the report offers a thorough regional study of the global Peptide-Drug Conjugates market. Drivers and restraints for each region are broadly examined in the report. Readers will get familiar with the driving forces and challenges that are specific to the regions. The specialists have identified growth opportunities in key geographical regions and their respective countries to aid players to reinforce their presence. All the regions and their countries in the report are assessed based on the growth rate and revenue according to the consumption for the period 2017-2028. This geographical analysis will help readers to gain in-depth knowledge of the regional growth. The key geographical regions surveyed in this research report involve North America, Europe, Asia Pacific, Central and South America, and Middle East and Africa. The report has specifically covered major countries including United States, Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
Key Players
This section has provided an exhaustive analysis of the strategies that the companies are focusing on to stay ahead of other players. The strategies mainly involve research and development, new product developments, and mergers and acquisitions. The researchers have also provided revenue shares of the key companies, company overview, and the latest company developments so as to help players to sustain the cutthroat competition. In this section, the report offers global revenue data of manufacturers for the period 2017-2022. Following is the list of key manufacturers observed in this research study:
AstraZeneca
Bicycle Therapeutics
Cybrexa Therapeutics
Esperance Pharmaceuticals
Oncopeptides
Pepgen Corporation
Soricimed Biopharma
Theratechnologies
Frequently Asked Questions
Which application segment captured the leading share in the Peptide-Drug Conjugates market?
How fragmented is the Peptide-Drug Conjugates market?
Which are the key growth drivers in the Peptide-Drug Conjugates market?
Which are the top strategies undertaken by the Peptide-Drug Conjugates market players?
Which technological trends are likely to affect the Peptide-Drug Conjugates market?
What is the expected Peptide-Drug Conjugates market size by 2028?
Which companies are dominating the Peptide-Drug Conjugates market?
Which region is projected to witness the fastest growth in the future?
What factors are restraining the Peptide-Drug Conjugates market growth?
Which are the emerging companies in the Peptide-Drug Conjugates market?
Table of Contents
1 Market Overview of Peptide-Drug Conjugates
- 1.1 Peptide-Drug Conjugates Market Overview
- 1.1.1 Peptide-Drug Conjugates Product Scope
- 1.1.2 Peptide-Drug Conjugates Market Status and Outlook
- 1.2 Global Peptide-Drug Conjugates Market Size Overview by Region 2017 VS 2021 VS 2028
- 1.3 Global Peptide-Drug Conjugates Market Size by Region (2017-2028)
- 1.4 Global Peptide-Drug Conjugates Historic Market Size by Region (2017-2022)
- 1.5 Global Peptide-Drug Conjugates Market Size Forecast by Region (2023-2028)
- 1.6 Key Regions, Peptide-Drug Conjugates Market Size (2017-2028)
- 1.6.1 North America Peptide-Drug Conjugates Market Size (2017-2028)
- 1.6.2 Europe Peptide-Drug Conjugates Market Size (2017-2028)
- 1.6.3 Asia-Pacific Peptide-Drug Conjugates Market Size (2017-2028)
- 1.6.4 Latin America Peptide-Drug Conjugates Market Size (2017-2028)
- 1.6.5 Middle East & Africa Peptide-Drug Conjugates Market Size (2017-2028)
2 Peptide-Drug Conjugates Market Overview by Type
- 2.1 Global Peptide-Drug Conjugates Market Size by Type: 2017 VS 2021 VS 2028
- 2.2 Global Peptide-Drug Conjugates Historic Market Size by Type (2017-2022)
- 2.3 Global Peptide-Drug Conjugates Forecasted Market Size by Type (2023-2028)
- 2.4 Cell-penetrating Peptides (CPPs)
- 2.5 Cell-targeting Peptides (CTPs)
3 Peptide-Drug Conjugates Market Overview by Application
- 3.1 Global Peptide-Drug Conjugates Market Size by Application: 2017 VS 2021 VS 2028
- 3.2 Global Peptide-Drug Conjugates Historic Market Size by Application (2017-2022)
- 3.3 Global Peptide-Drug Conjugates Forecasted Market Size by Application (2023-2028)
- 3.4 Carcinoma
- 3.5 Sarcoma
- 3.6 Melanoma
- 3.7 Lymphoma
- 3.8 Leukemia
4 Peptide-Drug Conjugates Competition Analysis by Players
- 4.1 Global Peptide-Drug Conjugates Market Size by Players (2017-2022)
- 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide-Drug Conjugates as of 2021)
- 4.3 Date of Key Players Enter into Peptide-Drug Conjugates Market
- 4.4 Global Top Players Peptide-Drug Conjugates Headquarters and Area Served
- 4.5 Key Players Peptide-Drug Conjugates Product Solution and Service
- 4.6 Competitive Status
- 4.6.1 Peptide-Drug Conjugates Market Concentration Rate
- 4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
- 5.1 AstraZeneca
- 5.1.1 AstraZeneca Profile
- 5.1.2 AstraZeneca Main Business
- 5.1.3 AstraZeneca Peptide-Drug Conjugates Products, Services and Solutions
- 5.1.4 AstraZeneca Peptide-Drug Conjugates Revenue (US$ Million) & (2017-2022)
- 5.1.5 AstraZeneca Recent Developments
- 5.2 Bicycle Therapeutics
- 5.2.1 Bicycle Therapeutics Profile
- 5.2.2 Bicycle Therapeutics Main Business
- 5.2.3 Bicycle Therapeutics Peptide-Drug Conjugates Products, Services and Solutions
- 5.2.4 Bicycle Therapeutics Peptide-Drug Conjugates Revenue (US$ Million) & (2017-2022)
- 5.2.5 Bicycle Therapeutics Recent Developments
- 5.3 Cybrexa Therapeutics
- 5.3.1 Cybrexa Therapeutics Profile
- 5.3.2 Cybrexa Therapeutics Main Business
- 5.3.3 Cybrexa Therapeutics Peptide-Drug Conjugates Products, Services and Solutions
- 5.3.4 Cybrexa Therapeutics Peptide-Drug Conjugates Revenue (US$ Million) & (2017-2022)
- 5.3.5 Esperance Pharmaceuticals Recent Developments
- 5.4 Esperance Pharmaceuticals
- 5.4.1 Esperance Pharmaceuticals Profile
- 5.4.2 Esperance Pharmaceuticals Main Business
- 5.4.3 Esperance Pharmaceuticals Peptide-Drug Conjugates Products, Services and Solutions
- 5.4.4 Esperance Pharmaceuticals Peptide-Drug Conjugates Revenue (US$ Million) & (2017-2022)
- 5.4.5 Esperance Pharmaceuticals Recent Developments
- 5.5 Oncopeptides
- 5.5.1 Oncopeptides Profile
- 5.5.2 Oncopeptides Main Business
- 5.5.3 Oncopeptides Peptide-Drug Conjugates Products, Services and Solutions
- 5.5.4 Oncopeptides Peptide-Drug Conjugates Revenue (US$ Million) & (2017-2022)
- 5.5.5 Oncopeptides Recent Developments
- 5.6 Pepgen Corporation
- 5.6.1 Pepgen Corporation Profile
- 5.6.2 Pepgen Corporation Main Business
- 5.6.3 Pepgen Corporation Peptide-Drug Conjugates Products, Services and Solutions
- 5.6.4 Pepgen Corporation Peptide-Drug Conjugates Revenue (US$ Million) & (2017-2022)
- 5.6.5 Pepgen Corporation Recent Developments
- 5.7 Soricimed Biopharma
- 5.7.1 Soricimed Biopharma Profile
- 5.7.2 Soricimed Biopharma Main Business
- 5.7.3 Soricimed Biopharma Peptide-Drug Conjugates Products, Services and Solutions
- 5.7.4 Soricimed Biopharma Peptide-Drug Conjugates Revenue (US$ Million) & (2017-2022)
- 5.7.5 Soricimed Biopharma Recent Developments
- 5.8 Theratechnologies
- 5.8.1 Theratechnologies Profile
- 5.8.2 Theratechnologies Main Business
- 5.8.3 Theratechnologies Peptide-Drug Conjugates Products, Services and Solutions
- 5.8.4 Theratechnologies Peptide-Drug Conjugates Revenue (US$ Million) & (2017-2022)
- 5.8.5 Theratechnologies Recent Developments
6 North America
- 6.1 North America Peptide-Drug Conjugates Market Size by Country (2017-2028)
- 6.2 United States
- 6.3 Canada
7 Europe
- 7.1 Europe Peptide-Drug Conjugates Market Size by Country (2017-2028)
- 7.2 Germany
- 7.3 France
- 7.4 U.K.
- 7.5 Italy
- 7.6 Russia
8 Asia-Pacific
- 8.1 Asia-Pacific Peptide-Drug Conjugates Market Size by Region (2017-2028)
- 8.2 China
- 8.3 Japan
- 8.4 South Korea
- 8.5 India
- 8.6 Australia
- 8.7 China Taiwan
- 8.8 Indonesia
9 Latin America
- 9.1 Latin America Peptide-Drug Conjugates Market Size by Country (2017-2028)
- 9.2 Mexico
- 9.3 Brazil
- 9.4 Argentina
10 Middle East & Africa
- 10.1 Middle East & Africa Peptide-Drug Conjugates Market Size by Country (2017-2028)
- 10.2 Turkey
- 10.3 Saudi Arabia
- 10.4 UAE
11 Peptide-Drug Conjugates Market Dynamics
- 11.1 Peptide-Drug Conjugates Industry Trends
- 11.2 Peptide-Drug Conjugates Market Drivers
- 11.3 Peptide-Drug Conjugates Market Challenges
- 11.4 Peptide-Drug Conjugates Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Disclaimer
Summary:
Get latest Market Research Reports on Peptide-Drug Conjugates. Industry analysis & Market Report on Peptide-Drug Conjugates is a syndicated market report, published as Global Peptide-Drug Conjugates Market Report, History and Forecast 2017-2028, Breakdown Data by Companies, Key Regions, Types and Application. It is complete Research Study and Industry Analysis of Peptide-Drug Conjugates market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
